8-K: Biogen Reports Strong Q1 2026 Results, Boosted by Growth Products

Biogen announced robust first quarter 2026 financial results, with total revenue reaching $2.5 billion and GAAP diluted EPS surging 31% year-over-year, driven by strong performance in its growth products and pipeline advancements.

Summary

• Biogen reported first quarter 2026 total revenue of $2.5 billion, a 2% increase year-over-year.
• GAAP diluted Earnings Per Share (EPS) rose 31% to $2.15, while Non-GAAP diluted EPS increased 18% to $3.57.
• Growth products, including SKYCLARYS, QALSODY, ZURZUVAE, VUMERITY, and SPINRAZA, along with Biogen's share of LEQEMBI revenue, collectively grew 12% year-over-year.
• LEQEMBI generated $168 million in global in-market sales, up 74% year-over-year, with U.S. sales at $86 million.
• SKYCLARYS revenue was $151 million, up 22% year-over-year, and ZURZUVAE revenue reached $55 million, up 100% year-over-year.
• SPINRAZA global revenue declined 12% to $374 million, impacted by shipment timing outside the U.S.
• QALSODY revenue grew 110% year-over-year to $33 million.
• The company announced an updated full-year 2026 Non-GAAP diluted EPS guidance of $14.25 to $15.25, excluding the impact of the Apellis transaction.
• Full-year 2026 total revenue is expected to decline by a mid-single digit percentage compared to 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong EPS growth and significant pipeline advancements, although tempered by a projected mid-single digit revenue decline for the full year and the impact of IPR&D charges on guidance.

Positives

• Total revenue increased by 2% year-over-year to $2.5 billion.
• GAAP diluted EPS saw a significant increase of 31% year-over-year, reaching $2.15.
• Non-GAAP diluted EPS grew by 18% year-over-year to $3.57.
• Growth products demonstrated strong commercial execution with 12% year-over-year growth.
• LEQEMBI's global in-market sales surged 74% year-over-year to $168 million.
• SKYCLARYS revenue increased by 22% year-over-year to $151 million.
• ZURZUVAE revenue doubled year-over-year to $55 million.
• QALSODY revenue more than doubled, increasing 110% year-over-year to $33 million.
• The proposed acquisition of Apellis Pharmaceuticals is expected to bolster revenue and earnings growth and be accretive in 2027.
• New data from pipeline programs, including Litifilimab and Salanersen, show promising results.
• LEQEMBI real-world persistence data indicates approximately 78% of patients continued treatment at 18 months.
• Net cash flow from operations was $646 million, and free cash flow was $594 million for the quarter.
• The effective tax rate decreased year-over-year to 15.4% (GAAP) and 15.3% (Non-GAAP).

Negatives

• SPINRAZA global revenue declined 12% year-over-year to $374 million, primarily due to the timing of shipments outside the U.S.
• Total revenue is projected to decline by a mid-single digit percentage for the full year 2026 compared to 2025.
• The company updated its full-year 2026 Non-GAAP diluted EPS guidance downwards by approximately $1.00 due to acquired IPR&D charges.
• Multiple sclerosis (MS) product revenue saw a slight decline of 3% year-over-year, excluding specific adjustments.
• Contract manufacturing, royalty and other revenue decreased by 16% year-over-year.

Risks

• The proposed acquisition of Apellis Pharmaceuticals is subject to customary closing conditions and regulatory approvals.
• Drug development and commercialization involve a high degree of risk, with only a small number of R&D programs resulting in commercialization.
• Clinical trial results may not be replicated in later stages or lead to regulatory approval.
• Increased product competition in the biopharmaceutical and healthcare industry poses a risk.
• Failure to obtain, protect, and enforce intellectual property rights could impact the business.
• Adverse safety events, restrictions on product use, or product liability claims could arise.
• Cybersecurity incidents impacting IT systems could disrupt operations.
• Risks associated with international business, including geopolitical tensions and large-scale crises.

Future Outlook

Full year 2026 Non-GAAP diluted EPS is now expected to be between $14.25 and $15.25, excluding any impact from the Apellis transaction. This updated guidance includes an approximately $1.00 impact from acquired IPR&D charges. Full year 2026 total revenue is expected to decline by a mid-single digit percentage versus full year 2025. Updated guidance inclusive of the Apellis transaction will be provided when second quarter 2026 earnings are reported.

Management Comments

• "We significantly advanced our transformation into the New Biogen through strong commercial and pipeline execution and the announcement of our intent to acquire Apellis."
• "We believe the planned acquisition of Apellis will bolster our revenue and earnings growth, adding two differentiated commercial medicines and deepening the foundation for felzartamab, our key Phase 3 asset in kidney disease."
• "This acquisition and the acquired rights to felzartamab in China come while we also expanded sales of our growth products, demonstrated continued resilience in our MS portfolio and reported important positive new data that reinforce our confidence in the latestage pipeline."

Industry Context

StockSavvy.ai notes that Biogen's Q1 2026 results reflect the ongoing strategic shift within the biotechnology sector towards acquiring commercial-stage assets and strengthening pipeline depth, particularly in areas like neurology and immunology. The company's performance, especially with its growth products and the LEQEMBI collaboration, aligns with broader industry trends of focusing on specialized therapies with significant market potential.

Comparison to Industry Standards

• Biogen's reported 2% year-over-year revenue growth in Q1 2026 is modest compared to some high-growth biotech peers, but strong within the context of a mature MS portfolio and the early stages of new product launches.
• The 31% year-over-year increase in GAAP diluted EPS is a significant positive, outperforming many industry benchmarks for companies undergoing transformation and investment.
• LEQEMBI's 74% year-over-year sales growth is a strong indicator of market adoption for new Alzheimer's treatments, a segment where many companies are investing heavily.
• The planned acquisition of Apellis Pharmaceuticals is a common strategy in the industry to accelerate growth and diversify revenue streams, similar to moves seen by other large pharmaceutical and biotech firms seeking to bolster their portfolios.

Stakeholder Impact

• Shareholders: Potential for increased value through the proposed Apellis acquisition and continued pipeline development, balanced by a projected mid-single digit revenue decline for the year.
• Employees: Continued investment in late-stage programs and business development may create opportunities, alongside ongoing cost-saving initiatives.
• Customers: Access to growing revenue products like LEQEMBI and SKYCLARYS, with potential for new therapies from pipeline advancements.
• Creditors: The company maintains a net debt of $1.5 billion, with $4.7 billion in cash and cash equivalents, indicating a stable financial position.

Next Steps

• Biogen plans to provide updated 2026 guidance inclusive of the Apellis transaction when it reports second quarter 2026 earnings.
• Continued development and commercialization of pipeline programs, including litifilimab and felzartamab.
• Integration of acquired rights to felzartamab in the Greater China region.
• Completion of the proposed acquisition of Apellis Pharmaceuticals, subject to customary closing conditions.

Key Dates

Recommendation

The company shows strong EPS growth and promising pipeline developments, particularly with the planned Apellis acquisition. However, the projected mid-single digit revenue decline for the full year and the impact of IPR&D charges on guidance warrant a cautious 'hold' rating until the full impact of the Apellis acquisition and future revenue trends become clearer.

Keywords

Biogen, SEC Filing, 8-K, Q1 2026 Earnings, Biotechnology, Pharmaceuticals, Financial Results, LEQEMBI